Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced a 10-year manufacturing supply agreement, valued at over $3 billion (€2.64 billion), with Regeneron Pharmaceuticals to provide US-based production of its industry-leading biologic medicines, which treat millions of patients worldwide.
Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some analysts, while others project a prolonged slump due to inflation and global instability. Established pharmaceutical companies are often seen as safer investments, with larger developers expected to perform well in 2023, especially if litigation threats against drugs like Zantac disappear. However, concerns about revenue gaps continue for big companies like GSK and Sanofi, and their strategy and leadership will be closely monitored in the coming months.
US biotech Regeneron is buying compatriot clinical-stage biopharma Checkmate Pharmaceuticals for a total equity value of about $250 million. The acquisition, expected to close in mid-2022, will boost Regeneron’s portfolio of diverse and combinable immuno-oncology candidates.
US biotech Regeneron is collaborating with AstraZeneca to research, develop and commercialize small molecule medicines targeting GPR75 for treating obesity.
